Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병배 | - |
dc.date.accessioned | 2018-03-15T07:17:25Z | - |
dc.date.available | 2018-03-15T07:17:25Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.citation | Blood Research, 권: 49, 호: 2, 페이지: 107-114 | en_US |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://www.synapse.koreamed.org/search.php?where=aview&id=10.5045/br.2014.49.2.107&code=3072BR&vmode=FULL | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/47328 | - |
dc.description.abstract | BackgroundWe investigated factors that influence outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab combined with the CHOP regimen (R-CHOP) followed by upfront autologous stem cell transplantation (Auto-SCT).MethodsWe retrospectively evaluated survival differences between subgroups based on the age-adjusted International Prognostic Index (aaIPI) and revised-IPI (R-IPI) at diagnosis, disease status, and positron emission tomographic/computerized tomographic (PET/CT) status at transplantation in 51 CD20-positive DLBCL patients treated with R-CHOP fol-lowed by upfront Auto-SCT.ResultsPatients had either stage I/II bulky disease (5.9%) or stage III/IV disease (94.1%). The me-dian patient age at diagnosis was 47 years (range, 22?66 years); 53.3% and 26.7% had high-intermediate and high risks according to aaIPI, respectively. At the time of Auto-SCT, 72.5% and 27.5% experienced complete (CR) and partial remission (PR) after R-CHOP, respectively. The median time from diagnosis to Auto-SCT was 7.27 months (range, 3.4?13.4 months). The 5-year overall (OS) and progression-free survival (PFS) were 77.3% and 72.4%, respectively. The 5-year OS and PFS rates according to aaIPI, R-IPI, and PET/CT status did not differ between the subgroups. More importantly, the 5-year OS and PFS rates of the patients who achieved PR at the time of Auto-SCT were not inferior to those of the patients who achieved CR (P=0.223 and 0.292, respectively).ConclusionSurvival was not influenced by the aaIPI and R-IPI at diagnosis, disease status, or PET/CT status at transplantation, suggesting that upfront Auto-SCT might overcome unfavorable outcomes attributed to PR after induction chemoimmunotherapy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | 대한혈액학회 | en_US |
dc.subject | Diffuse large B-cell lymphoma | en_US |
dc.subject | Hematopoietic stem cell transplantation | en_US |
dc.subject | Autologous transplantation | en_US |
dc.subject | Rituximab | en_US |
dc.subject | Survival analysis | en_US |
dc.title | R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 49 | - |
dc.relation.page | 107-114 | - |
dc.relation.journal | Blood Research | - |
dc.contributor.googleauthor | Lee, Hong-Ghi | - |
dc.contributor.googleauthor | Choi, Yun-suk | - |
dc.contributor.googleauthor | Kim, Sung-Yong | - |
dc.contributor.googleauthor | Kim, In-ho | - |
dc.contributor.googleauthor | Kim, Yeo-Kyeoung | - |
dc.contributor.googleauthor | Kim, Yang-Soo | - |
dc.contributor.googleauthor | Lee, Ho-Sup | - |
dc.contributor.googleauthor | Kim, Seok-Jin | - |
dc.contributor.googleauthor | Park, Byeong-Bae | - |
dc.contributor.googleauthor | Park, Jin-ny | - |
dc.relation.code | 2014041268 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | bbpark | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.